These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 368763)

  • 1. [Clinical pharmacology of isoniazid (a review of the literature)].
    Ivleva AIa
    Probl Tuberk; 1979 Jan; (1):18-26. PubMed ID: 368763
    [No Abstract]   [Full Text] [Related]  

  • 2. [Determination of the phenotype of INH inactivation in pulmonary tuberculosis by means of an indirect method on the model of sulfamethazine].
    Powłowska I; Rakowska Z
    Pneumonol Pol; 1978 Aug; 46(8):605-12. PubMed ID: 714703
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical pharmacology of isoniazid].
    Sokolova GV; Ivleva AIa; Ziia AV; Zeliger LR; Suvorova VI
    Probl Tuberk; 1984 Sep; (9):55-60. PubMed ID: 6504886
    [No Abstract]   [Full Text] [Related]  

  • 4. Importance of acetylation and oxidation in inactivation of isonicotinic acid hydrazide preparations.
    Smirnov GA
    Fed Proc Transl Suppl; 1966; 25(1):72-6. PubMed ID: 5322111
    [No Abstract]   [Full Text] [Related]  

  • 5. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Cas Lek Cesk; 1984 Feb; 123(6):158-64. PubMed ID: 6697364
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hepatotoxic effect of isoniazid (clinical, genetic and metabolic aspects)].
    Chrostowski K; Kanabus P
    Pneumonol Pol; 1977; 45(1):49-54. PubMed ID: 834577
    [No Abstract]   [Full Text] [Related]  

  • 7. [Incidence of hepatic changes in relation to the isoniazid acetylator phenotype].
    Pilheu JA; De Salvo MC; Manchinu I; de Negroni NR; Szemzo J
    Medicina (B Aires); 1980; 40(4):382-6. PubMed ID: 7207170
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment.
    Alarcón-Segovia D; Fishbein E; Alcalá H
    Arthritis Rheum; 1971; 14(6):748-52. PubMed ID: 5316358
    [No Abstract]   [Full Text] [Related]  

  • 9. [The influence of rifampicin upon the metabolism of isoniazid (author's transl)].
    Modai J; Coulaud JP; Vivien JM; Berthelot G; Bergogne-Berezin E
    Nouv Presse Med; 1978 Apr; 7(15):1263-7. PubMed ID: 662655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.
    Ellard GA
    Tubercle; 1984 Sep; 65(3):211-27. PubMed ID: 6385429
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of acetyl hydrazines and rate of acetylation of isoniazid in adult tuberculosis patients.
    Bhalerao EB; Bhide SV
    Indian J Physiol Pharmacol; 1985; 29(2):83-8. PubMed ID: 4093196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
    Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
    Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic factors in drug therapy.
    Evans DA
    Sci Basis Med Annu Rev; 1969; ():166-82. PubMed ID: 4918368
    [No Abstract]   [Full Text] [Related]  

  • 15. [Phenotype of isoniazid acetylation and tolerance of antitubercular drugs].
    Gontsa FT; Savina LA; Tsurkan VP; Kovalenko IP
    Probl Tuberk; 1988; (2):35-8. PubMed ID: 3375215
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rate of acetylation of isoniazid in pulmonary tuberculosis and its relationship with effect and side-effects of treatment (author's transl)].
    Zhang LX
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1981 Dec; 4(6):349-51. PubMed ID: 7344873
    [No Abstract]   [Full Text] [Related]  

  • 17. [Genetic polymorphism of isoniazid acetylation in Chilean patients with tuberculosis].
    Ligueros M; Cruz Coke R; Neira S; Saavedra H; Kramer V; Prieto JC; Gelman M; Saavedra A; Nuñez A; Pescio S
    Rev Med Chil; 1989 Dec; 117(12):1339-43. PubMed ID: 2519370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylation phenotype profile in north Indian children with pulmonary tuberculosis.
    Seth V; Beotra A; Ray D
    Indian Pediatr; 1987 Nov; 24(11):1007-10. PubMed ID: 3450638
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients].
    Kislitsyna NA
    Probl Tuberk; 1985; (4):55-7. PubMed ID: 4001111
    [No Abstract]   [Full Text] [Related]  

  • 20. Population screening for isoniazid acetylator phenotype.
    Seifart HI; Parkin DP; Botha FJ; Donald PR; Van Der Walt BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(2):127-34. PubMed ID: 11499851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.